You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
《大行報告》花旗降三生製藥(01530.HK)評級至「中性」 目標價下調至10元
阿思達克 04-23 10:21
花旗發表報告指,三生製藥(01530.HK)去年收入按年增長16%至53億元人民幣,純利則下跌24%至9.74億元人民幣(撇除一次性項目為按年升19%)。

該行預期,三生製藥今年業績表現會面臨挑戰,其中旗下主要藥品益賽普(YSP)需面對更多競爭,包括價格更為便宜的修美樂(Humira),而且國內市場亦有更多生物仿製藥推出。此外,另一主要藥品特比澳(TPIAO)的獨家性亦受到挑戰,因市場有更多的小分子血小板生成素(TPO)藥品加入競爭。

花旗下調三生製藥股份評級,由「買入」降至「中性」,目標價由16元下調至10元,並調低集團主要藥品今年的銷售預測。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account